485:
3291:
31:
3301:
3327:
780:(CLL) are encouraging, with a 95% overall response rate demonstrating potential to become a best-in-class treatment for CLL. Notably, a 100% response rate was achieved for those people which were positive for the 17p13.1 gene deletion, a subgroup that typically results in a poor response to therapy and expected outcomes.
682:
The most common adverse events were headache, diarrhea and weight gain. Despite the appearance of a greater occurrence of transient headaches, data suggest a preferred advantage of acalabrutinib over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.
768:
or otherwise virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In addition, in platelets treated with ibrutinib, thrombus formation was clearly inhibited while no impact to thrombus formation was identified relative to
649:
inhibitor. Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.
673:
In the United States, acalabrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
735:
purchased a 55% stake in Acerta Pharma for $ 4 billion in
December 2015, with an option to acquire the remaining 45% stake for an additional $ 3 billion, conditional on approval in both the US and Europe and the establishment of commercial opportunity.
769:
controls for those treated with acalabrutinib. These findings strongly suggest an improved safety profile of acalabrutinib with minimized adverse effects relative to ibrutinib. In pre-clinical studies, it was shown to be more potent and selective than
669:
for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL). It is also indicated for the treatment of adults with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
596:
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
208:
1508:
554:
1328:
163:
1501:
1442:
938:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1942:
1927:
776:
The interim results of the still on-going first human phase I/II clinical trial (NCT02029443) with 61 patients for the treatment of relapsed
61:
1005:
3017:
568:
1494:
849:
1413:
World Health
Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75".
3362:
3202:
2500:
2143:
880:
764:, acalabrutinib demonstrated higher selectivity and inhibition of the targeted activity of BTK, while having a much greater IC
720:
2939:
1186:
1157:
1636:
3357:
112:
2614:
1302:
3072:
3057:
745:
696:
Acalabrutinib was approved for medical use in the United States in 2017, and in the
European Union in November 2020.
653:
Acalabrutinib was approved for medical use in the United States in 2017, and in the
European Union in November 2020.
588:
1380:
2034:
1560:
827:
1463:
1353:
723:, WM). Approval would result in a 10-year period of market exclusivity for the stated indications within Europe.
259:
193:
93:
630:/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.
3172:
3347:
3245:
1273:
1244:
1215:
3304:
2380:
1192:
1163:
1011:
777:
708:
627:
480:
365:
948:
434:
3367:
2561:
1537:
646:
1486:
3317:
2686:
2535:
2284:
1786:
749:
716:
2932:
2011:
1877:
1590:
1329:"AstraZeneca and Acerta Pharma's acalabrutinib tagged an Orphan Drug in Europe for three indications"
1278:
1249:
1220:
924:
712:
1475:
2021:
1547:
3352:
3240:
1517:
149:
43:
3276:
3192:
3187:
3082:
2389:
1872:
1601:
731:
It was developed by Acerta Pharma. After promising results for CLL in initial clinical trials,
455:
414:
919:
354:
3372:
3147:
3012:
1947:
1887:
1857:
1760:
1596:
1042:
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. (January 2016).
715:(EMA) Committee for Orphan Medicinal Products (COMP) for treatment of three indications: CLL/
666:
642:
289:
3294:
2925:
1802:
1697:
1534:
704:
623:
619:
374:
484:
8:
2655:
1922:
1912:
1732:
634:
280:
156:
2310:
1847:
1134:
1107:
1068:
1043:
123:
3032:
1987:
1388:
1139:
1073:
980:
797:
445:
314:
232:
220:
85:
71:
823:
1827:
1669:
1664:
1422:
1129:
1119:
1063:
1055:
497:
176:
3331:
3162:
3002:
2972:
2764:
2662:
2610:
2208:
1521:
1124:
22:
3341:
3027:
2982:
2821:
2711:
2673:
2650:
2582:
2577:
2343:
2339:
2327:
2134:
1917:
1882:
1702:
1682:
1392:
854:
638:
473:
3271:
3217:
3207:
3137:
3047:
2997:
2992:
2861:
2846:
2816:
2796:
2678:
2626:
2587:
2475:
2454:
2361:
2323:
2224:
2199:
2195:
2079:
2044:
1997:
1982:
1937:
1812:
1782:
1707:
1525:
1143:
1077:
732:
711:(CLL), and was similarly designated as an orphan medicinal product by the
662:
661:
In the
European Union, acalabrutinib as monotherapy or in combination with
171:
1059:
3212:
3167:
3157:
3152:
3132:
3127:
3112:
3107:
3092:
3062:
3022:
2977:
2967:
2948:
2891:
2871:
2866:
2856:
2836:
2811:
2806:
2789:
2737:
2727:
2722:
2717:
2619:
2546:
2516:
2511:
2506:
2490:
2480:
2460:
2335:
2331:
2319:
2315:
2244:
2148:
2094:
2089:
2054:
1992:
1977:
1967:
1962:
1957:
1952:
1932:
1897:
1852:
1832:
1822:
1777:
1742:
1722:
1678:
1641:
1629:
1624:
1586:
1570:
1516:
700:
79:
1427:
334:
3197:
3182:
3142:
3122:
3102:
3087:
3042:
3037:
3007:
2906:
2901:
2876:
2841:
2826:
2801:
2784:
2774:
2732:
2703:
2668:
2634:
2551:
2541:
2521:
2485:
2470:
2465:
2435:
2369:
2365:
2347:
2295:
2274:
2234:
2229:
2168:
2099:
2074:
2049:
1972:
1907:
1867:
1862:
1842:
1837:
1817:
1807:
1797:
1712:
1692:
1674:
1582:
530:
345:
1108:"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor"
3250:
3177:
3077:
3067:
3052:
2896:
2886:
2881:
2851:
2831:
2779:
2769:
2757:
2752:
2698:
2693:
2639:
2572:
2445:
2440:
2425:
2420:
2415:
2405:
2400:
2395:
2300:
2290:
2269:
2264:
2259:
2254:
2249:
2239:
2219:
2183:
2178:
2173:
2163:
2158:
2125:
2120:
2115:
2084:
2064:
2059:
1902:
1892:
1717:
1565:
770:
761:
300:
65:
3235:
3117:
3097:
2987:
2646:
2410:
2214:
2153:
2109:
2069:
2039:
1792:
1656:
1652:
1577:
719:(SLL), mantle cell lymphoma (MCL), and lymphoplasmacytic lymphoma (
394:
325:
107:
1044:"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia"
553:
461:
1750:
1006:"FDA approves new treatment for adults with mantle cell lymphoma"
30:
3255:
425:
2917:
1041:
2630:
2356:
2190:
2139:
1619:
544:
405:
2745:
2531:
2029:
1755:
1737:
1727:
1687:
1555:
385:
1412:
576:
CC#CC(=O)N1CCC1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
633:
Common side effects include headaches, feeling tired,
3315:
875:
873:
1187:"Acalabrutinib Orphan Drug Designation and Approval"
1158:"Acalabrutinib Orphan Drug Designation and Approval"
881:"Calquence- acalabrutinib capsule, gelatin coated"
870:
790:
1354:"AstraZeneca to buy Acerta for blood cancer drug"
618:, is a medication used to treat various types of
3339:
914:
912:
910:
908:
906:
904:
902:
798:"Acalabrutinib (Calquence) Use During Pregnancy"
699:As of February 2016, acalabrutinib had received
313:
850:"Summary Basis of Decision (SBD) for Calquence"
288:
1360:. Chemistry World - Royal Society of Chemistry
2933:
1502:
899:
3018:Budesonide/glycopyrronium bromide/formoterol
1378:
111:
1381:"AstraZeneca to Buy Stake in Acerta Pharma"
1037:
1035:
1033:
1031:
981:"Acalabrutinib Monograph for Professionals"
2940:
2926:
1509:
1495:
1105:
1101:
1099:
1097:
1095:
1093:
1091:
1089:
1087:
975:
973:
971:
969:
483:
353:
29:
1426:
1133:
1123:
1067:
373:
1028:
1379:Walker I, Roland D (17 December 2015).
1084:
966:
333:
84:
3340:
686:
474:
238:
2921:
1490:
1326:
703:designation in the United States for
454:
433:
413:
226:
102:
70:
3300:
1112:Journal of Hematology & Oncology
953:Union Register of medicinal products
773:, the first-in-class BTK inhibitor.
460:
175:
1106:Wu J, Zhang M, Liu D (March 2016).
1048:The New England Journal of Medicine
393:
304:
13:
267:4-{8-Amino-3-imidazopyrazin-1-yl}-
14:
3384:
3073:Glycopyrronium bromide/formoterol
1456:
746:international nonproprietary name
202:
134:
3325:
3299:
3290:
3289:
1016:(Press release). 31 October 2017
828:Therapeutic Goods Administration
721:Waldenström's macroglobulinaemia
514:
508:
2947:
1435:
1406:
1372:
1346:
1320:
1295:
1266:
1237:
1208:
1179:
1150:
949:"Calquence Product information"
691:
677:
656:
601:Key:WDENQIQQYWYTPO-IBGZPJMESA-N
3363:Drugs developed by AstraZeneca
3173:Sodium zirconium cyclosilicate
998:
941:
842:
816:
520:
502:
215:
1:
3246:Cambridge Antibody Technology
1327:House DW (25 February 2016).
783:
1470:. National Cancer Institute.
1193:Food and Drug Administration
1164:Food and Drug Administration
1012:Food and Drug Administration
778:chronic lymphocytic leukemia
726:
709:chronic lymphocytic leukemia
645:. It is a second generation
628:chronic lymphocytic leukemia
614:, sold under the brand name
7:
755:
10:
3389:
3358:Tyrosine kinase inhibitors
2012:Tyrosine kinase inhibitors
750:United States Adopted Name
717:small lymphocytic lymphoma
492:Chemical and physical data
3285:
3264:
3226:
2955:
2602:
2379:
2020:
2010:
1878:Mirvetuximab soravtansine
1770:
1651:
1611:
1546:
1533:
1480:National Cancer Institute
1279:European Medicines Agency
1250:European Medicines Agency
1221:European Medicines Agency
1125:10.1186/s13045-016-0250-9
925:European Medicines Agency
713:European Medicines Agency
584:
564:
542:
529:
496:
491:
472:
444:
424:
404:
384:
364:
344:
324:
299:
279:
255:
250:
192:
187:
162:
148:
122:
92:
78:
60:
52:
42:
37:
28:
2022:Receptor tyrosine kinase
1548:Receptor tyrosine kinase
739:
647:Bruton's tyrosine kinase
3241:Alexion Pharmaceuticals
1612:Others for solid tumors
1518:Targeted cancer therapy
271:-(2-pyridinyl)benzamide
3193:Trastuzumab deruxtecan
3188:Tixagevimab/cilgavimab
3083:Isosorbide mononitrate
1873:Loncastuximab tesirine
1602:Trastuzumab deruxtecan
3148:Salbutamol/budesonide
3013:Budesonide/formoterol
1948:Sacituzumab govitecan
1888:Moxetumomab pasudotox
1858:Inotuzumab ozogamicin
1761:Gemtuzumab ozogamicin
1597:Trastuzumab emtansine
1538:monoclonal antibodies
1522:antineoplastic agents
1060:10.1056/NEJMoa1509981
744:Acalabrutinib is the
643:low white blood cells
3348:Antineoplastic drugs
1803:Belantamab mafodotin
1415:WHO Drug Information
705:mantle cell lymphoma
624:mantle cell lymphoma
620:non-Hodgkin lymphoma
2656:Denileukin diftitox
2318:(ALK, ROS1, NTRK),
1923:Polatuzumab vedotin
1913:Oportuzumab monatox
1468:NCI Drug Dictionary
1385:Wall Street Journal
1303:"azn201602256k.htm"
687:Society and culture
635:low red blood cells
211:(Prescription only)
25:
3368:Alkyne derivatives
3229:acquired companies
2342:(ROS1, TRK, ALK),
1848:Enfortumab vedotin
1482:. 3 November 2017.
1448:. 27 January 2016.
887:. 22 November 2019
830:. 13 December 2019
21:
3313:
3312:
3033:Disufenton sodium
2915:
2914:
2598:
2597:
2006:
2005:
1988:Tisotumab vedotin
858:. 23 October 2014
804:. 23 October 2019
609:
608:
555:Interactive image
242:
230:
218:
206:
138:
105:
16:Chemical compound
3380:
3330:
3329:
3328:
3321:
3303:
3302:
3293:
3292:
3277:Louis Schweitzer
3227:Predecessors and
2942:
2935:
2928:
2919:
2918:
2629:peptide against
2202:(AXL, ALK, LTK))
2018:
2017:
1828:Dinutuximab beta
1544:
1543:
1511:
1504:
1497:
1488:
1487:
1483:
1471:
1450:
1449:
1447:
1439:
1433:
1432:
1430:
1410:
1404:
1403:
1401:
1399:
1376:
1370:
1369:
1367:
1365:
1350:
1344:
1343:
1341:
1339:
1324:
1318:
1317:
1315:
1313:
1299:
1293:
1292:
1290:
1288:
1270:
1264:
1263:
1261:
1259:
1241:
1235:
1234:
1232:
1230:
1212:
1206:
1205:
1203:
1201:
1183:
1177:
1176:
1174:
1172:
1154:
1148:
1147:
1137:
1127:
1103:
1082:
1081:
1071:
1039:
1026:
1025:
1023:
1021:
1002:
996:
995:
993:
991:
977:
964:
963:
961:
959:
945:
939:
937:
935:
933:
920:"Calquence EPAR"
916:
897:
896:
894:
892:
877:
868:
867:
865:
863:
846:
840:
839:
837:
835:
820:
814:
813:
811:
809:
794:
557:
537:
522:
516:
510:
504:
487:
476:
464:
458:
437:
417:
397:
377:
357:
337:
317:
307:
306:
292:
240:
237:
228:
225:
217:
214:
204:
201:
179:
136:
133:
115:
104:
101:
88:
74:
33:
26:
24:
20:
3388:
3387:
3383:
3382:
3381:
3379:
3378:
3377:
3338:
3337:
3336:
3326:
3324:
3316:
3314:
3309:
3281:
3260:
3228:
3222:
3163:Sebelipase alfa
3003:Brompheniramine
2951:
2946:
2916:
2911:
2765:Pi3K inhibitors
2663:mTOR inhibitors
2594:
2375:
2346:(VEGFR, FGFR),
2002:
1766:
1647:
1607:
1529:
1515:
1476:"Acalabrutinib"
1474:
1464:"Acalabrutinib"
1462:
1459:
1454:
1453:
1445:
1443:"Acalabrutinib"
1441:
1440:
1436:
1411:
1407:
1397:
1395:
1377:
1373:
1363:
1361:
1352:
1351:
1347:
1337:
1335:
1325:
1321:
1311:
1309:
1301:
1300:
1296:
1286:
1284:
1272:
1271:
1267:
1257:
1255:
1243:
1242:
1238:
1228:
1226:
1214:
1213:
1209:
1199:
1197:
1185:
1184:
1180:
1170:
1168:
1156:
1155:
1151:
1104:
1085:
1040:
1029:
1019:
1017:
1004:
1003:
999:
989:
987:
979:
978:
967:
957:
955:
947:
946:
942:
931:
929:
918:
917:
900:
890:
888:
879:
878:
871:
861:
859:
848:
847:
843:
833:
831:
822:
821:
817:
807:
805:
796:
795:
791:
786:
767:
758:
748:(INN), and the
742:
729:
694:
689:
680:
659:
605:
602:
597:
592:
591:
580:
577:
572:
571:
560:
535:
525:
519:
513:
507:
468:
440:
420:
400:
380:
360:
340:
320:
303:
295:
275:
272:
263:
262:
246:
183:
151:
144:
125:
118:
17:
12:
11:
5:
3386:
3376:
3375:
3370:
3365:
3360:
3355:
3353:Human proteins
3350:
3335:
3334:
3311:
3310:
3308:
3307:
3297:
3286:
3283:
3282:
3280:
3279:
3274:
3268:
3266:
3262:
3261:
3259:
3258:
3253:
3248:
3243:
3238:
3232:
3230:
3224:
3223:
3221:
3220:
3215:
3210:
3205:
3200:
3195:
3190:
3185:
3180:
3175:
3170:
3165:
3160:
3155:
3150:
3145:
3140:
3135:
3130:
3125:
3120:
3115:
3110:
3105:
3100:
3095:
3090:
3085:
3080:
3075:
3070:
3065:
3060:
3055:
3050:
3045:
3040:
3035:
3030:
3025:
3020:
3015:
3010:
3005:
3000:
2995:
2990:
2985:
2980:
2975:
2973:Andexanet alfa
2970:
2965:
2959:
2957:
2953:
2952:
2945:
2944:
2937:
2930:
2922:
2913:
2912:
2910:
2909:
2904:
2899:
2894:
2889:
2884:
2879:
2874:
2869:
2864:
2859:
2854:
2849:
2844:
2839:
2834:
2829:
2824:
2819:
2814:
2809:
2804:
2799:
2794:
2793:
2792:
2787:
2782:
2777:
2772:
2762:
2761:
2760:
2755:
2742:
2741:
2740:
2735:
2730:
2725:
2720:
2712:CDK inhibitors
2708:
2707:
2706:
2701:
2696:
2683:
2682:
2681:
2676:
2671:
2659:
2643:
2623:
2611:fusion protein
2606:
2604:
2600:
2599:
2596:
2595:
2593:
2592:
2591:
2590:
2585:
2580:
2575:
2570:
2557:
2556:
2555:
2554:
2549:
2544:
2527:
2526:
2525:
2524:
2519:
2514:
2509:
2496:
2495:
2494:
2493:
2488:
2483:
2478:
2473:
2468:
2463:
2450:
2449:
2443:
2431:
2430:
2429:
2428:
2423:
2418:
2413:
2408:
2403:
2398:
2385:
2383:
2377:
2376:
2374:
2373:
2352:
2351:
2350:(VEGFR, EGFR).
2306:
2305:
2304:
2303:
2298:
2293:
2280:
2279:
2278:
2277:
2272:
2267:
2262:
2257:
2252:
2247:
2242:
2237:
2232:
2227:
2222:
2217:
2204:
2203:
2187:
2181:
2176:
2171:
2166:
2161:
2156:
2151:
2131:
2130:
2129:
2128:
2123:
2118:
2108:HER1/EGFR and
2104:
2103:
2097:
2092:
2087:
2082:
2077:
2072:
2067:
2062:
2057:
2052:
2047:
2042:
2026:
2024:
2015:
2008:
2007:
2004:
2003:
2001:
2000:
1995:
1990:
1985:
1980:
1975:
1970:
1965:
1960:
1955:
1950:
1945:
1940:
1935:
1930:
1925:
1920:
1915:
1910:
1905:
1900:
1895:
1890:
1885:
1880:
1875:
1870:
1865:
1860:
1855:
1850:
1845:
1840:
1835:
1830:
1825:
1820:
1815:
1810:
1805:
1800:
1795:
1790:
1787:+hyaluronidase
1780:
1774:
1772:
1768:
1767:
1765:
1764:
1747:
1746:
1720:
1715:
1710:
1705:
1700:
1695:
1661:
1659:
1649:
1648:
1646:
1645:
1633:
1627:
1615:
1613:
1609:
1608:
1606:
1605:
1599:
1594:
1591:+hyaluronidase
1574:
1568:
1552:
1550:
1541:
1531:
1530:
1514:
1513:
1506:
1499:
1491:
1485:
1484:
1472:
1458:
1457:External links
1455:
1452:
1451:
1434:
1405:
1371:
1345:
1319:
1294:
1274:"EU/3/16/1626"
1265:
1245:"EU/3/16/1625"
1236:
1216:"EU/3/16/1624"
1207:
1178:
1149:
1083:
1054:(4): 323–332.
1027:
997:
965:
940:
928:. 20 July 2020
898:
869:
841:
815:
788:
787:
785:
782:
765:
757:
754:
741:
738:
728:
725:
693:
690:
688:
685:
679:
676:
658:
655:
607:
606:
604:
603:
600:
598:
595:
587:
586:
585:
582:
581:
579:
578:
575:
567:
566:
565:
562:
561:
559:
558:
550:
548:
540:
539:
533:
527:
526:
523:
517:
511:
505:
500:
494:
493:
489:
488:
478:
470:
469:
467:
466:
450:
448:
442:
441:
439:
438:
430:
428:
422:
421:
419:
418:
410:
408:
402:
401:
399:
398:
390:
388:
382:
381:
379:
378:
370:
368:
362:
361:
359:
358:
350:
348:
342:
341:
339:
338:
330:
328:
322:
321:
319:
318:
310:
308:
297:
296:
294:
293:
285:
283:
277:
276:
274:
273:
266:
258:
257:
256:
253:
252:
248:
247:
245:
244:
235:
223:
212:
198:
196:
190:
189:
185:
184:
182:
181:
168:
166:
160:
159:
154:
152:administration
146:
145:
143:
142:
140:
130:
128:
120:
119:
117:
116:
98:
96:
90:
89:
82:
76:
75:
68:
58:
57:
54:
50:
49:
46:
40:
39:
35:
34:
15:
9:
6:
4:
3:
2:
3385:
3374:
3371:
3369:
3366:
3364:
3361:
3359:
3356:
3354:
3351:
3349:
3346:
3345:
3343:
3333:
3323:
3322:
3319:
3306:
3298:
3296:
3288:
3287:
3284:
3278:
3275:
3273:
3270:
3269:
3267:
3263:
3257:
3254:
3252:
3249:
3247:
3244:
3242:
3239:
3237:
3234:
3233:
3231:
3225:
3219:
3216:
3214:
3211:
3209:
3206:
3204:
3201:
3199:
3196:
3194:
3191:
3189:
3186:
3184:
3181:
3179:
3176:
3174:
3171:
3169:
3166:
3164:
3161:
3159:
3156:
3154:
3151:
3149:
3146:
3144:
3141:
3139:
3136:
3134:
3131:
3129:
3126:
3124:
3121:
3119:
3116:
3114:
3111:
3109:
3106:
3104:
3101:
3099:
3096:
3094:
3091:
3089:
3086:
3084:
3081:
3079:
3076:
3074:
3071:
3069:
3066:
3064:
3061:
3059:
3056:
3054:
3051:
3049:
3046:
3044:
3041:
3039:
3036:
3034:
3031:
3029:
3028:Dapagliflozin
3026:
3024:
3021:
3019:
3016:
3014:
3011:
3009:
3006:
3004:
3001:
2999:
2996:
2994:
2991:
2989:
2986:
2984:
2983:Asfotase alfa
2981:
2979:
2976:
2974:
2971:
2969:
2966:
2964:
2963:Acalabrutinib
2961:
2960:
2958:
2954:
2950:
2943:
2938:
2936:
2931:
2929:
2924:
2923:
2920:
2908:
2905:
2903:
2900:
2898:
2895:
2893:
2890:
2888:
2885:
2883:
2880:
2878:
2875:
2873:
2870:
2868:
2865:
2863:
2860:
2858:
2855:
2853:
2850:
2848:
2845:
2843:
2840:
2838:
2835:
2833:
2830:
2828:
2825:
2823:
2822:Larotrectinib
2820:
2818:
2815:
2813:
2810:
2808:
2805:
2803:
2800:
2798:
2795:
2791:
2788:
2786:
2783:
2781:
2778:
2776:
2773:
2771:
2768:
2767:
2766:
2763:
2759:
2756:
2754:
2751:
2750:
2749:
2747:
2743:
2739:
2736:
2734:
2731:
2729:
2726:
2724:
2721:
2719:
2716:
2715:
2714:
2713:
2709:
2705:
2702:
2700:
2697:
2695:
2692:
2691:
2690:
2688:
2684:
2680:
2677:
2675:
2674:Ridaforolimus
2672:
2670:
2667:
2666:
2665:
2664:
2660:
2657:
2653:
2652:
2648:
2644:
2641:
2637:
2636:
2632:
2628:
2624:
2621:
2617:
2616:
2612:
2608:
2607:
2605:
2601:
2589:
2586:
2584:
2583:Pirtobrutinib
2581:
2579:
2578:Orelabrutinib
2576:
2574:
2571:
2569:
2568:Acalabrutinib
2566:
2565:
2564:
2563:
2559:
2558:
2553:
2550:
2548:
2545:
2543:
2540:
2539:
2538:
2537:
2533:
2529:
2528:
2523:
2520:
2518:
2515:
2513:
2510:
2508:
2505:
2504:
2503:
2502:
2498:
2497:
2492:
2489:
2487:
2484:
2482:
2479:
2477:
2474:
2472:
2469:
2467:
2464:
2462:
2459:
2458:
2457:
2456:
2452:
2451:
2447:
2444:
2442:
2438:
2437:
2433:
2432:
2427:
2424:
2422:
2419:
2417:
2414:
2412:
2409:
2407:
2404:
2402:
2399:
2397:
2394:
2393:
2392:
2391:
2387:
2386:
2384:
2382:
2378:
2371:
2367:
2363:
2360:
2358:
2354:
2353:
2349:
2345:
2344:Selpercatinib
2341:
2340:Repotrectinib
2337:
2333:
2329:
2328:Larotrectinib
2325:
2321:
2317:
2314:
2312:
2308:
2307:
2302:
2299:
2297:
2294:
2292:
2289:
2288:
2287:
2286:
2282:
2281:
2276:
2273:
2271:
2268:
2266:
2263:
2261:
2258:
2256:
2253:
2251:
2248:
2246:
2243:
2241:
2238:
2236:
2233:
2231:
2228:
2226:
2223:
2221:
2218:
2216:
2213:
2212:
2211:
2210:
2206:
2205:
2201:
2197:
2193:
2192:
2188:
2185:
2182:
2180:
2177:
2175:
2172:
2170:
2167:
2165:
2162:
2160:
2157:
2155:
2152:
2150:
2146:
2145:
2141:
2136:
2135:RTK class III
2133:
2132:
2127:
2124:
2122:
2119:
2117:
2114:
2113:
2112:
2111:
2106:
2105:
2101:
2098:
2096:
2093:
2091:
2088:
2086:
2083:
2081:
2078:
2076:
2073:
2071:
2068:
2066:
2063:
2061:
2058:
2056:
2053:
2051:
2048:
2046:
2043:
2041:
2037:
2036:
2031:
2028:
2027:
2025:
2023:
2019:
2016:
2013:
2009:
1999:
1996:
1994:
1991:
1989:
1986:
1984:
1981:
1979:
1976:
1974:
1971:
1969:
1966:
1964:
1961:
1959:
1956:
1954:
1951:
1949:
1946:
1944:
1941:
1939:
1936:
1934:
1931:
1929:
1926:
1924:
1921:
1919:
1918:Pembrolizumab
1916:
1914:
1911:
1909:
1906:
1904:
1901:
1899:
1896:
1894:
1891:
1889:
1886:
1884:
1883:Mogamulizumab
1881:
1879:
1876:
1874:
1871:
1869:
1866:
1864:
1861:
1859:
1856:
1854:
1851:
1849:
1846:
1844:
1841:
1839:
1836:
1834:
1831:
1829:
1826:
1824:
1821:
1819:
1816:
1814:
1811:
1809:
1806:
1804:
1801:
1799:
1796:
1794:
1791:
1788:
1784:
1781:
1779:
1776:
1775:
1773:
1769:
1762:
1758:
1757:
1752:
1749:
1748:
1744:
1740:
1739:
1734:
1730:
1729:
1724:
1721:
1719:
1716:
1714:
1711:
1709:
1706:
1704:
1703:Mosunetuzumab
1701:
1699:
1696:
1694:
1690:
1689:
1684:
1683:Mosunetuzumab
1680:
1676:
1672:
1671:
1666:
1663:
1662:
1660:
1658:
1654:
1650:
1643:
1639:
1638:
1634:
1631:
1628:
1626:
1622:
1621:
1617:
1616:
1614:
1610:
1603:
1600:
1598:
1595:
1592:
1588:
1584:
1580:
1579:
1575:
1572:
1569:
1567:
1563:
1562:
1557:
1554:
1553:
1551:
1549:
1545:
1542:
1539:
1536:
1532:
1527:
1523:
1519:
1512:
1507:
1505:
1500:
1498:
1493:
1492:
1489:
1481:
1477:
1473:
1469:
1465:
1461:
1460:
1444:
1438:
1429:
1424:
1420:
1416:
1409:
1394:
1390:
1386:
1382:
1375:
1359:
1355:
1349:
1334:
1333:Seeking Alpha
1330:
1323:
1308:
1304:
1298:
1282:
1280:
1275:
1269:
1253:
1251:
1246:
1240:
1224:
1222:
1217:
1211:
1196:
1194:
1188:
1182:
1167:
1165:
1159:
1153:
1145:
1141:
1136:
1131:
1126:
1121:
1117:
1113:
1109:
1102:
1100:
1098:
1096:
1094:
1092:
1090:
1088:
1079:
1075:
1070:
1065:
1061:
1057:
1053:
1049:
1045:
1038:
1036:
1034:
1032:
1015:
1013:
1007:
1001:
986:
982:
976:
974:
972:
970:
954:
950:
944:
927:
926:
921:
915:
913:
911:
909:
907:
905:
903:
886:
882:
876:
874:
857:
856:
855:Health Canada
851:
845:
829:
825:
819:
803:
799:
793:
789:
781:
779:
774:
772:
763:
753:
751:
747:
737:
734:
724:
722:
718:
714:
710:
706:
702:
697:
684:
675:
671:
668:
664:
654:
651:
648:
644:
640:
639:low platelets
636:
631:
629:
625:
621:
617:
613:
612:Acalabrutinib
599:
594:
593:
590:
583:
574:
573:
570:
563:
556:
552:
551:
549:
546:
541:
534:
532:
528:
501:
499:
495:
490:
486:
482:
479:
477:
475:ECHA InfoCard
471:
463:
462:RCSB PDB
457:
452:
451:
449:
447:
443:
436:
435:ChEMBL3707348
432:
431:
429:
427:
423:
416:
412:
411:
409:
407:
403:
396:
392:
391:
389:
387:
383:
376:
372:
371:
369:
367:
363:
356:
352:
351:
349:
347:
343:
336:
332:
331:
329:
327:
323:
316:
312:
311:
309:
302:
298:
291:
287:
286:
284:
282:
278:
270:
265:
264:
261:
254:
249:
243: Rx-only
236:
234:
224:
222:
213:
210:
200:
199:
197:
195:
191:
186:
178:
173:
170:
169:
167:
165:
161:
158:
155:
153:
147:
141:
132:
131:
129:
127:
121:
114:
113:Acalabrutinib
109:
100:
99:
97:
95:
91:
87:
83:
81:
77:
73:
69:
67:
63:
59:
55:
51:
47:
45:
41:
38:Clinical data
36:
32:
27:
23:Acalabrutinib
19:
3373:Orphan drugs
3272:Tom McKillop
3218:Zolmitriptan
3208:Ximelagatran
3138:Rosuvastatin
3048:Esomeprazole
2998:Bicalutamide
2993:Benralizumab
2962:
2862:Pexidartinib
2847:Odronextamab
2817:Gilteritinib
2797:Cabozantinib
2744:
2710:
2685:
2679:Temsirolimus
2661:
2645:
2627:proapoptotic
2625:
2609:
2588:Zanubrutinib
2567:
2560:
2530:
2499:
2476:Lestaurtinib
2455:Janus kinase
2453:
2434:
2388:
2381:Non-receptor
2362:Cabozantinib
2355:
2324:Infigratinib
2309:
2283:
2225:Fruquintinib
2207:
2200:Gilteritinib
2196:Lestaurtinib
2189:
2138:
2107:
2080:Mobocertinib
2045:Aumolertinib
2033:
1998:Tremelimumab
1983:Tislelizumab
1938:Retifanlimab
1813:Blinatumomab
1783:Atezolizumab
1754:
1736:
1726:
1708:Obinutuzumab
1686:
1668:
1635:
1618:
1576:
1559:
1479:
1467:
1437:
1428:10665/331046
1418:
1414:
1408:
1396:. Retrieved
1384:
1374:
1362:. Retrieved
1357:
1348:
1336:. Retrieved
1332:
1322:
1310:. Retrieved
1306:
1297:
1285:. Retrieved
1283:. 4 May 2016
1277:
1268:
1256:. Retrieved
1254:. 4 May 2016
1248:
1239:
1227:. Retrieved
1225:. 2 May 2016
1219:
1210:
1198:. Retrieved
1190:
1181:
1169:. Retrieved
1161:
1152:
1115:
1111:
1051:
1047:
1018:. Retrieved
1009:
1000:
988:. Retrieved
984:
956:. Retrieved
952:
943:
930:. Retrieved
923:
889:. Retrieved
884:
860:. Retrieved
853:
844:
832:. Retrieved
818:
806:. Retrieved
801:
792:
775:
760:Relative to
759:
743:
733:Astra Zeneca
730:
698:
695:
692:Legal status
681:
678:Side effects
672:
663:obinutuzumab
660:
657:Medical uses
652:
632:
622:, including
615:
611:
610:
415:CHEBI:167707
290:1420477-60-6
268:
194:Legal status
188:Legal status
94:License data
18:
3213:Zafirlukast
3168:Selumetinib
3158:Saxagliptin
3153:Savolitinib
3133:Roflumilast
3128:Ravulizumab
3113:Palivizumab
3108:Osimertinib
3093:Motavizumab
3063:Fulvestrant
3023:Candesartan
2978:Anifrolumab
2968:Anastrozole
2949:AstraZeneca
2892:Tebentafusp
2872:Regorafenib
2867:Quizartinib
2857:Pemigatinib
2837:Midostaurin
2812:Erdafitinib
2807:Entrectinib
2790:Parsaclisib
2738:Trilaciclib
2728:Palbociclib
2723:Dalpiciclib
2718:Abemaciclib
2620:Aflibercept
2547:Entrectinib
2517:Selumetinib
2512:Cobimetinib
2507:Binimetinib
2491:Ruxolitinib
2481:Momelotinib
2461:Baricitinib
2359:inhibitors:
2336:Pralsetinib
2332:Pemigatinib
2320:Futibatinib
2316:Entrectinib
2313:inhibitors:
2245:Regorafenib
2149:Avapritinib
2095:Rociletinib
2090:Osimertinib
2055:Dacomitinib
1993:Toripalimab
1978:Teclistamab
1968:Talquetamab
1963:Tafasitamab
1958:Sugemalimab
1953:Serplulimab
1943:Sabatolimab
1933:Ramucirumab
1928:Prolgolimab
1898:Necitumumab
1853:Epcoritamab
1833:Dostarlimab
1823:Daratumumab
1778:Amivantamab
1743:Alemtuzumab
1733:Brentuximab
1723:Tositumomab
1698:Ibritumomab
1679:Elranatamab
1642:Bevacizumab
1630:Edrecolomab
1625:Catumaxomab
1587:Trastuzumab
1571:Panitumumab
1398:19 November
1364:24 December
1358:www.rsc.org
1338:21 November
1312:21 November
1307:www.sec.gov
932:11 November
891:11 November
824:"Calquence"
701:orphan drug
538: g·mol
481:100.247.121
251:Identifiers
80:MedlinePlus
53:Other names
44:Trade names
3342:Categories
3198:Vandetanib
3183:Ticagrelor
3143:Roxadustat
3123:Quetiapine
3103:Omeprazole
3088:Metoprolol
3043:Eculizumab
3038:Durvalumab
3008:Budesonide
2907:Venetoclax
2902:Vandetanib
2877:Ripretinib
2842:Nintedanib
2827:Lenvatinib
2802:Capmatinib
2785:Idelalisib
2775:Copanlisib
2748:inhibitors
2733:Ribociclib
2704:Vismodegib
2689:inhibitors
2669:Everolimus
2635:prohibitin
2552:Lorlatinib
2542:Crizotinib
2522:Trametinib
2486:Pacritinib
2471:Filgotinib
2466:Fedratinib
2370:Crizotinib
2366:Capmatinib
2348:Vandetanib
2296:Brigatinib
2275:Vandetanib
2235:Nintedanib
2230:Lenvatinib
2169:Ripretinib
2100:Vandetanib
2075:Lazertinib
2050:Brigatinib
1973:Tarlatamab
1908:Olaratumab
1868:Isatuximab
1863:Ipilimumab
1843:Elotuzumab
1838:Durvalumab
1818:Cemiplimab
1808:Bermekimab
1798:Axatilimab
1713:Ofatumumab
1693:Glofitamab
1675:Glofitamab
1583:Pertuzumab
784:References
626:(MCL) and
543:3D model (
531:Molar mass
446:PDB ligand
375:I42748ELQW
346:ChemSpider
281:CAS Number
260:IUPAC name
3251:MedImmune
3203:Vaxzevria
3178:Tamoxifen
3078:Goserelin
3068:Gefitinib
3053:Exenatide
2897:Tepotinib
2887:Sunitinib
2882:Sorafenib
2852:Pazopanib
2832:Masitinib
2780:Duvelisib
2770:Alpelisib
2758:Sotorasib
2753:Adagrasib
2699:Sonidegib
2694:Glasdegib
2640:Adipotide
2573:Ibrutinib
2446:Dasatinib
2441:Bosutinib
2426:Radotinib
2421:Ponatinib
2416:Nilotinib
2406:Dasatinib
2401:Bosutinib
2396:Asciminib
2364:(VEGFR),
2322:(FGFR2),
2301:Ceritinib
2291:Alectinib
2270:Toceranib
2265:Tivozanib
2260:Sunitinib
2255:Sorafenib
2250:Semaxanib
2240:Pazopanib
2220:Cediranib
2184:Toceranib
2179:Sunitinib
2174:Sorafenib
2164:Pazopanib
2159:Masitinib
2126:Tucatinib
2121:Neratinib
2116:Lapatinib
2085:Olmutinib
2065:Gefitinib
2060:Erlotinib
2035:HER1/EGFR
1903:Nivolumab
1893:Naxitamab
1718:Rituximab
1566:Cetuximab
1561:HER1/EGFR
1421:(1): 94.
1393:0099-9660
985:Drugs.com
834:31 August
802:Drugs.com
771:ibrutinib
762:ibrutinib
727:Economics
667:indicated
616:Calquence
150:Routes of
124:Pregnancy
72:Monograph
66:Drugs.com
48:Calquence
3332:Medicine
3295:Category
3236:Astra AB
3118:Propofol
3098:Olaparib
2988:Atenolol
2956:Products
2687:hedgehog
2649:against
2647:exotoxin
2613:against
2562:Bruton's
2411:Imatinib
2334:(FGFR),
2330:(NTRK),
2215:Axitinib
2154:Axitinib
2110:HER2/neu
2070:Icotinib
2040:Afatinib
2014:("-nib")
1793:Avelumab
1665:lymphoid
1657:lymphoma
1653:Leukemia
1578:HER2/neu
1540:("-mab")
1287:15 April
1258:15 April
1229:15 April
1200:15 April
1171:15 April
1144:26957112
1078:26641137
1020:28 March
990:16 March
885:DailyMed
808:28 March
756:Research
752:(USAN).
355:36764951
326:DrugBank
315:71226662
164:ATC code
157:By mouth
126:category
108:DailyMed
3305:Commons
3058:FluMist
2390:bcr-abl
1751:myeloid
1135:4784459
1069:4862586
958:3 March
536:465.517
498:Formula
335:DB11703
301:PubChem
219::
180:)
174: (
172:L01EL02
139: C
110::
86:a618004
56:ACP-196
3318:Portal
3265:People
3256:Zeneca
1637:VEGF-A
1391:
1142:
1132:
1118:: 21.
1076:
1066:
862:29 May
641:, and
569:SMILES
426:ChEMBL
395:D10893
233:â„ž-only
231:
221:â„ž-only
207:
106:
2631:ANXA2
2603:Other
2501:MAP2K
2372:(ALK)
2357:c-MET
2209:VEGFR
2144:PDGFR
2140:C-kit
1771:Other
1620:EpCAM
1446:(PDF)
1281:(EMA)
1252:(EMA)
1223:(EMA)
1195:(FDA)
1191:U.S.
1166:(FDA)
1162:U.S.
1014:(FDA)
1010:U.S.
740:Names
589:InChI
545:JSmol
453:XQQ (
406:ChEBI
2746:KRAS
2651:IL-2
2633:and
2615:VEGF
2532:EML4
2191:FLT3
2142:and
2030:ErbB
1756:CD33
1738:CD52
1728:CD30
1688:CD20
1556:ErbB
1400:2016
1389:ISSN
1366:2015
1340:2016
1314:2016
1289:2020
1260:2020
1231:2020
1202:2020
1173:2020
1140:PMID
1074:PMID
1022:2020
992:2019
960:2023
934:2020
893:2020
864:2022
836:2024
810:2020
707:and
456:PDBe
386:KEGG
366:UNII
62:AHFS
2536:ALK
2436:Src
2311:RET
2285:ALK
1735:),
1725:),
1685:),
1670:CD3
1526:L01
1423:hdl
1130:PMC
1120:doi
1064:PMC
1056:doi
1052:374
665:is
305:CID
177:WHO
3344::
2368:,
2338:,
2326:,
2198:,
2137::
2032::
1753::
1681:,
1677:,
1667::
1585:,
1558::
1535:CI
1520:/
1478:.
1466:.
1419:30
1417:.
1387:.
1383:.
1356:.
1331:.
1305:.
1276:.
1247:.
1218:.
1189:.
1160:.
1138:.
1128:.
1114:.
1110:.
1086:^
1072:.
1062:.
1050:.
1046:.
1030:^
1008:.
983:.
968:^
951:.
922:.
901:^
883:.
872:^
852:.
826:.
800:.
766:50
637:,
512:23
506:26
459:,
239:EU
227:US
216:CA
209:S4
203:AU
135:AU
103:US
3320::
2941:e
2934:t
2927:v
2658:)
2654:(
2642:)
2638:(
2622:)
2618:(
2534:-
2448:)
2439:(
2194:(
2186:)
2147:(
2102:)
2038:(
1789:)
1785:(
1763:)
1759:(
1745:)
1741:(
1731:(
1691:(
1673:(
1655:/
1644:)
1640:(
1632:)
1623:(
1604:)
1593:)
1589:(
1581:(
1573:)
1564:(
1528:)
1524:(
1510:e
1503:t
1496:v
1431:.
1425::
1402:.
1368:.
1342:.
1316:.
1291:.
1262:.
1233:.
1204:.
1175:.
1146:.
1122::
1116:9
1080:.
1058::
1024:.
994:.
962:.
936:.
895:.
866:.
838:.
812:.
547:)
524:2
521:O
518:7
515:N
509:H
503:C
465:)
269:N
241::
229::
205::
137::
64:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
